Furthermore, our study demonstrates that soluble, ADAM10‐cleaved sNrCAM is an excellent marker in AD patients for developing and testing drugs that selectively activate cleavage of APP over other ADAM10 substrates. This evidence concerns the gene APP and Alzheimer disease.